1. Home
  2. Directory
  3. New Jersey
  4. East Orange
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1154772614

DR. ERIN RENEE SHERMAN O.D.
Prescription History 1154772614
Optometrist in East Orange, NJ

NPI Status: Active since June 27, 2016

Contact Information

385 TREMONT AVE
EAST ORANGE, NJ
ZIP 07018
Phone: (973) 676-1000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ERIN RENEE SHERMAN O.D., an active Optometrist specialist practicing in East Orange, NJ. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 132 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 66 claims alone.

Medication Index

B
L
R
S
No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 22.5
Days Supply 654
NJ State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills85.4
Peer Average Days Supply2,439
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,256.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$173.61

State Avg Cost Per Claim

$63.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 66
30-Day Fills 89.1
Days Supply 2,350
NJ State Average Benchmarks
Peer Average Claims127.0
Peer Average 30-Day Fills224.7
Peer Average Days Supply6,385
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $713.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.81

State Avg Cost Per Claim

$24.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 600
NJ State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills131.1
Peer Average Days Supply3,800
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.6% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,270.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$418.03

State Avg Cost Per Claim

$475.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 24
30-Day Fills 36.0
Days Supply 1,065
NJ State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills117.2
Peer Average Days Supply3,471
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.2% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,787.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$907.81

State Avg Cost Per Claim

$1,136.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 320
NJ State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills48.7
Peer Average Days Supply1,425
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.8% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,792.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$199.46

State Avg Cost Per Claim

$274.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ERIN RENEE SHERMAN O.D. provides transparency into local medical care patterns within East Orange, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.